The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

Summary

COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects.

Timeline

Start

2025-01-21

Primary completion

2025-06-25

Completion

2025-06-26

Drugs

Indications